Shots:
- Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas
- As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization
- Lilly will gain exclusive global rights to certain programs & ex-Greater China rights to others, while Haisco retains rights in Greater China. Haisco is eligible for ~$87M in upfront & near-term payments, ~$2.967B in milestone payments, & tiered single-digit royalties on future sales
Ref: PRnewswire | Image: Haisco & Eli Lilly | Press Release
Related News: Haisco Partners with AbbVie to Develop Novel Medicines for Pain in a ~$745M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
